作者: 不要嚴(yán)酷 時(shí)間: 2025-3-21 23:11
Neoadjuvant Treatment in Rectal Cancer: Do We Always Need Radiotherapy–or Can We Risk Assess Locallygnancies (Birgisson et al. 2005; van Gijn et al. 2011). If preoperative radiotherapy does not impact on survival, can it be omitted in selected cases? The answer is yes—with the proviso that we are using good quality magnetic resonance imaging and good quality TME surgery within the mesorectal plane作者: yohimbine 時(shí)間: 2025-3-22 03:19 作者: fluoroscopy 時(shí)間: 2025-3-22 08:35
Adjuvant Therapy for Pancreatic Cancerin terms of survival parameters, though gemcitabine had a better toxicity profile. The results of these key studies, together with smaller ones have been subjected to meta-analyses, with confirmation of improved survival with adjuvant systemic chemotherapy. The EORTC-40891 and ESPAC-1 trials found n作者: LIKEN 時(shí)間: 2025-3-22 09:22 作者: 避開 時(shí)間: 2025-3-22 14:16 作者: 避開 時(shí)間: 2025-3-22 18:10
Open or Minimally Invasive Resection for Oesophageal Cancer?ar reduction in respiratory complications, although larger series suggest that MIO may have a benefit. Although MIO approaches report less lymph node retrieval compared with open extended lymphadenectomy, MIO cancer outcomes are comparable. MIO will be a major component of the future oesophageal sur作者: Budget 時(shí)間: 2025-3-22 22:48 作者: nutrients 時(shí)間: 2025-3-23 04:26 作者: 鴕鳥 時(shí)間: 2025-3-23 06:27 作者: 暴露他抗議 時(shí)間: 2025-3-23 10:25
0080-0015 atment of colorectal and pancreatic cancer are also discussed in some detail. This book will be of interest to every clinician involved in the care of patients with gastrointestinal malignancies.?978-3-642-44161-5978-3-642-31629-6Series ISSN 0080-0015 Series E-ISSN 2197-6767 作者: AGOG 時(shí)間: 2025-3-23 14:21
https://doi.org/10.1007/978-3-662-42950-1osed as novel early end point because the CRM status can account for effects on DFS and overall survival after chemoradiation, radiation (RT), or surgery alone. Consensus is needed to define the most appropriate end points in both early and phase III trials in locally advanced cancer.作者: Proponent 時(shí)間: 2025-3-23 22:02 作者: 哪有黃油 時(shí)間: 2025-3-24 00:24
https://doi.org/10.1007/978-3-662-33814-8tic operations are becoming increasingly utilised however and we examine the data available for their role. These operations include major venous and arterial resection, multivisceral resections and surgery for metastatic disease, or palliative pancreatic resection. Portal vein resection for local i作者: arterioles 時(shí)間: 2025-3-24 05:11
Verhandlungen des Hils-Solling-Forst-Vereinsin terms of survival parameters, though gemcitabine had a better toxicity profile. The results of these key studies, together with smaller ones have been subjected to meta-analyses, with confirmation of improved survival with adjuvant systemic chemotherapy. The EORTC-40891 and ESPAC-1 trials found n作者: 臨時(shí)抱佛腳 時(shí)間: 2025-3-24 07:50 作者: 護(hù)身符 時(shí)間: 2025-3-24 12:55
,Die Verkehrspunkte, — Siedlungen,res a holistic understanding of their net influence in the development of malignancy. This review explores the evidence base for established and putative risk factors in the development of gastric and oesophageal cancers. It is hoped that with a clear understanding of important risk factors, a multi作者: 鋼筆記下懲罰 時(shí)間: 2025-3-24 17:36 作者: Cursory 時(shí)間: 2025-3-24 20:02 作者: Acclaim 時(shí)間: 2025-3-24 23:58
Disturbi del comportamento alimentare, important option for patients unfit for surgery. In addition, it enables symptom relief in a palliative setting, namely dysphagia, pain, or bleeding. While target volumes are very much standardized, new technologies as image-guided intensity-modulated radiotherapy (IG-IMRT) and particle therapy hav作者: Anemia 時(shí)間: 2025-3-25 04:43 作者: 摻和 時(shí)間: 2025-3-25 07:51
0080-0015 ghlights areas of consensus and controversy in the care of pThis Recent Results in Cancer Research volume contains the majority of the invited expert contributions from the First St. Gallen EORTC Gastrointestinal Cancer Conference, held on 22-24 March 2012 in St. Gallen, Switzerland. Written by some作者: 存心 時(shí)間: 2025-3-25 13:36 作者: 鬧劇 時(shí)間: 2025-3-25 16:45 作者: SPECT 時(shí)間: 2025-3-25 22:02 作者: 掃興 時(shí)間: 2025-3-26 02:14
https://doi.org/10.1007/978-3-642-46412-6re, a novel endoscopic treatment, endoscopic submucosal dissection (ESD) was developed to resolve such disadvantage of EMR (Oyama and Kikuchi 2002; Oyama et al. 2005; Fujishiro et al. 2006; Ishihara et al. 2008; Hiroaki et al. 2010).作者: 小臼 時(shí)間: 2025-3-26 05:46 作者: 對(duì)手 時(shí)間: 2025-3-26 11:03
Treatment Dilemmas in Patients with Synchronous Colorectal Liver Metastasesronous resectable liver metastases? Unfortunately, there are no clear answers to these questions from prospective randomized trials. In the present article retrospective studies are analyzed in order to define the best possible treatment strategy for patients with synchronous colorectal liver metastases.作者: 連鎖 時(shí)間: 2025-3-26 13:14 作者: needle 時(shí)間: 2025-3-26 20:49
Conference proceedings 2012tified. While the principal focus is on esophageal and gastric cancer, advances in the treatment of colorectal and pancreatic cancer are also discussed in some detail. This book will be of interest to every clinician involved in the care of patients with gastrointestinal malignancies.?作者: CRATE 時(shí)間: 2025-3-27 00:13
Die Durchführung des Betriebsvergleichesy a response prediction by FDG–PET is not possible. The principle item of multimodal therapy is still transthoracic en bloc esophagectomy which should be performed in high volume centers in order to guarantee stable and good results.作者: 啜泣 時(shí)間: 2025-3-27 02:43
Choosing the Best Treatment for Esophageal Cancery a response prediction by FDG–PET is not possible. The principle item of multimodal therapy is still transthoracic en bloc esophagectomy which should be performed in high volume centers in order to guarantee stable and good results.作者: 的是兄弟 時(shí)間: 2025-3-27 07:10
Clinically Relevant Study End Points in Rectal Cancercontrol and survival. However, the use of a variety of response rates (i.e. pathological complete response, downsizing the primary tumor, tumor regression grade (TRG), radiological response) as endpoints in early (phase II) clinical trials is common since objective response to therapy is an early in作者: obstruct 時(shí)間: 2025-3-27 11:56 作者: subordinate 時(shí)間: 2025-3-27 17:08
Treatment Dilemmas in Patients with Synchronous Colorectal Liver Metastases determine the best treatment strategy in these patients. For example, should the primary tumor be removed in those patients with unresectable liver metastases and who do not have any symptoms of the primary tumor? Or which operation should be performed first in patients with rectal cancer and synch作者: 尾隨 時(shí)間: 2025-3-27 19:14
Pancreatic Surgery: Beyond the Traditional Limitsare of ductal origin but the incidence of cystic tumors such as intrapapillary mucinous tumors (IPMN) or mucinous cystic tumors (MCN) and other rare tumors is rising. Complete surgical resection of the tumor is the mainstay of any curative therapeutic approach, however, up to 40?% of patients with p作者: 步兵 時(shí)間: 2025-3-27 23:11 作者: chastise 時(shí)間: 2025-3-28 04:50 作者: 全部 時(shí)間: 2025-3-28 07:47
Adenocarcinoma Of the GEJ: Gastric or Oesophageal Cancer? folds regardless of where the bulk of the tumor lies. In addition, these neoplasms are now classified as esophageal cancers by UICC (2010). Recent studies, however, revealed two types of carcinogenesis in the distal oesophagus and at the GEJ, one of intestinal type (about 80?%) and the other of gas作者: cutlery 時(shí)間: 2025-3-28 13:34 作者: metropolitan 時(shí)間: 2025-3-28 14:49 作者: senile-dementia 時(shí)間: 2025-3-28 18:45 作者: 受辱 時(shí)間: 2025-3-29 00:36
Choosing the Best Treatment for Esophageal Cancerereas neoadjuvant chemotherapy is only appropriate for patients with adenocarcinoma. However, the 2-year survival benefit by this induction therapy compared to surgery alone is only 5–9?%. Targeted drugs seem to be promising in order to improve the response rate. The choice of the best multimodal th作者: regale 時(shí)間: 2025-3-29 03:36 作者: bronchodilator 時(shí)間: 2025-3-29 07:30
Radiotherapy of Gastroesophageal Junction CancerWhile early T1/2 N0 tumors are treated with surgery alone, they are only found in a small subset of patients due to the lack of symptoms at this stage. Most of the tumors are detected in locally advanced stage where surgery alone results in disappointing outcome. Chemotherapy and/or chemoirradiation作者: immunity 時(shí)間: 2025-3-29 15:00 作者: antiquated 時(shí)間: 2025-3-29 19:18
Early Gastrointestinal Cancers978-3-642-31629-6Series ISSN 0080-0015 Series E-ISSN 2197-6767 作者: 洞察力 時(shí)間: 2025-3-29 20:32 作者: Enliven 時(shí)間: 2025-3-30 01:44
978-3-642-44161-5Springer-Verlag Berlin Heidelberg 2012作者: manifestation 時(shí)間: 2025-3-30 05:16 作者: 責(zé)問 時(shí)間: 2025-3-30 10:56
Recent Results in Cancer Researchhttp://image.papertrans.cn/e/image/300728.jpg作者: 平淡而無味 時(shí)間: 2025-3-30 15:54
https://doi.org/10.1007/978-3-662-42950-1control and survival. However, the use of a variety of response rates (i.e. pathological complete response, downsizing the primary tumor, tumor regression grade (TRG), radiological response) as endpoints in early (phase II) clinical trials is common since objective response to therapy is an early in作者: Nebulizer 時(shí)間: 2025-3-30 16:32
https://doi.org/10.1007/978-3-662-41162-9pletely unexpected as radiotherapy is a localised treatment and local control may not prevent systemic failure. Optimal quality-controlled surgery for patients with operable rectal cancer in the trial setting can be associated with local recurrence rates of less than 10?% whether patients receive ra作者: 盤旋 時(shí)間: 2025-3-30 22:09
